Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 2
2008 3
2011 2
2012 3
2013 4
2014 6
2015 4
2016 6
2017 7
2018 7
2019 2
2020 10
2021 9
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.
Averbuch I, Tschernichovsky R, Yust-Katz S, Rotem O, Limon D, Kurman N, Icht O, Reinhorn D, Moskovitz M, Hanovich E, Benouaich-Amiel A, Siegal T, Zer A, Gal O. Averbuch I, et al. Among authors: yust katz s. J Neurooncol. 2024 Feb;166(3):461-469. doi: 10.1007/s11060-024-04562-0. Epub 2024 Feb 7. J Neurooncol. 2024. PMID: 38324192 Free PMC article.
Prevalence of pathogenic germline variants in adult-type diffuse glioma.
McDonald MF, Prather LL, Helfer CR, Ludmir EB, Echeverria AE, Yust-Katz S, Patel AJ, Deneen B, Rao G, Jalali A, Dhar SU, Amos CI, Mandel JJ. McDonald MF, et al. Among authors: yust katz s. Neurooncol Pract. 2023 Jun 21;10(5):482-490. doi: 10.1093/nop/npad033. eCollection 2023 Oct. Neurooncol Pract. 2023. PMID: 37720399 Free article.
A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
Bairey O, Taliansky A, Glik A, Amiel A, Yust-Katz S, Gurion R, Zektser M, Porges T, Sarid N, Horowitz NA, Shina TT, Lebel E, Cohen A, Geiger KR, Raanani P, Wolach O, Siegal T. Bairey O, et al. Among authors: yust katz s. Cancer. 2023 Dec 15;129(24):3905-3914. doi: 10.1002/cncr.34985. Epub 2023 Aug 12. Cancer. 2023. PMID: 37572086 Clinical Trial.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. Among authors: yust katz s. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Clinical Trial.
Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2.
Adler O, Zait Y, Cohen N, Blazquez R, Doron H, Monteran L, Scharff Y, Shami T, Mundhe D, Glehr G, Kanner AA, Horn S, Yahalom V, Haferkamp S, Hutchinson JA, Bleckmann A, Nahary L, Benhar I, Yust Katz S, Pukrop T, Erez N. Adler O, et al. Among authors: yust katz s. Nat Cancer. 2023 Mar;4(3):401-418. doi: 10.1038/s43018-023-00519-w. Epub 2023 Feb 16. Nat Cancer. 2023. PMID: 36797502
Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.
Peled N, Kian W, Inbar E, Goldstein IM, Zemel M, Rotem O, Rozenblum AB, Nechushtan H, Dudnik E, Levin D, Zer A, Keren-Rosenberg S, Yust-Katz S, Fuchs V, Remilah AA, Shelef I, Roisman LC. Peled N, et al. Among authors: yust katz s. Neurooncol Adv. 2021 Dec 27;4(1):vdab188. doi: 10.1093/noajnl/vdab188. eCollection 2022 Jan-Dec. Neurooncol Adv. 2021. PMID: 35156036 Free PMC article.
66 results